课题基金 / 基金详情

Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates

Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
桥接抗体 Fc 介导的人类和非人类灵长类动物的抗病毒功能
批准号:
9925737
负责人:
GEORGIA Doris TOMARAS
金额:
$410.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2024-04-30

项目摘要

项目成果

GEORGIA Doris TOMARAS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): HIV-1 vaccine efficacy trials and multiple animal studies, including those related to HIV-cure strategies, have shown that antibody interactions with cells - mediated by the antibody constant (Fc) region - can harness multiple aspects of the immune system to provide protection through mechanisms other than by neutralization. However, it is unknown whether candidate HIV-1 vaccine regimens that include induction of Fc-mediated antibody functions can be tested in the rhesus macaque (RM) nonhuman primate (NHP) in a way that can be translated to humans. In order to more effectively translate insights gained from RM studies to the clinic, there is a need to fully define the protective signatures of Fc-mediated antibody functions across rhesus macaques and humans. The work we propose will map antibody (Ab) and Fc-receptor (FcR) biology across humans and RMs with the goal of making observed protective responses in RMs more predictive of human responses, thus accelerating the most promising vaccine concepts to be advanced to the clinic with success. Our central hypothesis is that the RM model can be substantially improved for testing antibody-based interventions and vaccines through elucidation of key variables that impact species-specific FcγR-dependent effector functions (i.e. antibody epitope specificity, immune complex formation, isotype/subclass, glycosylation, and FcR genotype/phenotype). To test this, we propose three synergistic, inter-related scientific Projects supported by three Cores to achieve the following Overall Aims: Overall AIM 1. Characterize effective anti-HIV-1 Fc-FcR biology across RM to humans. Overall AIM 2. Define HIV-1 virion and infected cell epitopes for antibody recognition. Overall AIM 3. Determine the Fv and Fc features of antibodies yielding maximal anti-HIV-1 activity.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1080/19420862.2021.1882028
发表时间: 2021-01
期刊: mAbs
影响因子: 5.3
作者: [Chu TH, Patz EF Jr, Ackerman ME]
通讯作者: Ackerman ME
DOI: 10.1371/journal.ppat.1008764
发表时间: 2020-09
期刊: PLoS pathogens
影响因子: 6.7
作者: [Om K, Paquin-Proulx D, Montero M, Peachman K, Shen X, Wieczorek L, Beck Z, Weiner JA, Kim D, Li Y, Mdluli T, Shubin Z, Bryant C, Sharma V, Tokarev A, Dawson P, White Y, Appelbe O, Klatt NR, Tovanabutra S, Estes JD, Matyas GR, Ferrari G, Alving CR, Tomaras GD, Ackerman ME, Michael NL, Robb ML, Polonis V, Rolland M, Eller MA, Rao M, Bolton DL]
通讯作者: Bolton DL
DOI: 10.1097/coh.0000000000000638
发表时间: 2020-09
期刊: Current opinion in HIV and AIDS
影响因子: 4.1
作者: [Carpenter MC, Ackerman ME]
通讯作者: Ackerman ME
Impact of Antibody Effector Function Diversity on Antiviral Activity In Situ
  • 批准号:
    10258146
  • 项目类别:
  • 资助金额:
    $434.33万
  • 财政年份:
    2021
  • 负责人:
    GEORGIA Doris TOMARAS
  • 依托单位:
Mechanisms of Antibody Fc Mediated Protection
  • 批准号:
    10475284
  • 项目类别:
  • 资助金额:
    $59.14万
  • 财政年份:
    2021
  • 负责人:
    GEORGIA Doris TOMARAS
  • 依托单位:
Administrative Core
  • 批准号:
    10670243
  • 项目类别:
  • 资助金额:
    $25.9万
  • 财政年份:
    2021
  • 负责人:
    GEORGIA Doris TOMARAS
  • 依托单位:
Antiviral Activity In Situ
  • 批准号:
    10475294
  • 项目类别:
  • 资助金额:
    $85.28万
  • 财政年份:
    2021
  • 负责人:
    GEORGIA Doris TOMARAS
  • 依托单位:
海外基金